EW Quote, Financials, Valuation and Earnings

Artivion, Inc. has a net margin of 4.09% compared to Edwards Lifesciences Corp.'s net margin of 2.09%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Artivion, Inc.'s return on equity of 2.6%.

Edwards Lifesciences Corp. has a consensus price target of $96.50, signalling upside risk potential of 20.96%. On the other hand Artivion, Inc. has an analysts' consensus of $51.43 which suggests that it could grow by 34.17%. Given that Artivion, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe Artivion, Inc. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.939, which suggesting that the stock is 6.133% less volatile than S&P 500. In comparison Artivion, Inc. has a beta of 1.591, suggesting its more volatile than the S&P 500 by 59.114%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Artivion, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Artivion, Inc. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are larger than Artivion, Inc. quarterly revenues of $116M. Edwards Lifesciences Corp.'s net income of $64.2M is higher than Artivion, Inc.'s net income of $2.4M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 43.06x while Artivion, Inc.'s PE ratio is 191.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 7.70x versus 4.04x for Artivion, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

AtriCure, Inc. has a net margin of 4.09% compared to Edwards Lifesciences Corp.'s net margin of 1.25%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat AtriCure, Inc.'s return on equity of -2.44%.

Edwards Lifesciences Corp. has a consensus price target of $96.50, signalling upside risk potential of 20.96%. On the other hand AtriCure, Inc. has an analysts' consensus of $49.38 which suggests that it could grow by 49.72%. Given that AtriCure, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe AtriCure, Inc. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.939, which suggesting that the stock is 6.133% less volatile than S&P 500. In comparison AtriCure, Inc. has a beta of 1.415, suggesting its more volatile than the S&P 500 by 41.514%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AtriCure, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. AtriCure, Inc. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are larger than AtriCure, Inc. quarterly revenues of $140.5M. Edwards Lifesciences Corp.'s net income of $64.2M is higher than AtriCure, Inc.'s net income of $1.8M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 43.06x while AtriCure, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 7.70x versus 2.91x for AtriCure, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 4.09% compared to Edwards Lifesciences Corp.'s net margin of 12.68%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Boston Scientific Corp.'s return on equity of 12.55%.

Edwards Lifesciences Corp. has a consensus price target of $96.50, signalling upside risk potential of 20.96%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 40.45%. Given that Boston Scientific Corp. has higher upside potential than Edwards Lifesciences Corp., analysts believe Boston Scientific Corp. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.939, which suggesting that the stock is 6.133% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Edwards Lifesciences Corp.'s net income of $64.2M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 43.06x while Boston Scientific Corp.'s PE ratio is 38.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 7.70x versus 5.55x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 4.09% compared to Edwards Lifesciences Corp.'s net margin of 27.89%. Edwards Lifesciences Corp.'s return on equity of 13.19% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Edwards Lifesciences Corp. has a consensus price target of $96.50, signalling upside risk potential of 20.96%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 21.38%. Given that Intuitive Surgical, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe Intuitive Surgical, Inc. is more attractive than Edwards Lifesciences Corp..

Edwards Lifesciences Corp. has a beta of 0.939, which suggesting that the stock is 6.133% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Edwards Lifesciences Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edwards Lifesciences Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Edwards Lifesciences Corp. quarterly revenues are $1.6B, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Edwards Lifesciences Corp.'s net income of $64.2M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Edwards Lifesciences Corp.'s price-to-earnings ratio is 43.06x while Intuitive Surgical, Inc.'s PE ratio is 64.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edwards Lifesciences Corp. is 7.70x versus 18.17x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.